Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review.
| Autor: | Murphy MM; The University of Kansas Health System Kansas City, KS, USA., Patatanian E; College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA., Gales MA; College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Therapeutic advances in infectious disease [Ther Adv Infect Dis] 2018 Sep 12; Vol. 5 (6), pp. 111-119. Date of Electronic Publication: 2018 Sep 12 (Print Publication: 2018). |
| DOI: | 10.1177/2049936118798276 |
| Abstrakt: | Clostridium difficile infections have a high recurrence rate following acute treatment. Extended duration vancomycin (EDV) is a mainstay for the treatment of recurrent Clostridium difficile infections (rCDI). Clinical disease guidelines recommend a variety of different vancomycin treatment regimens though based on weak, low-quality evidence. Patients typically receive an initial vancomycin treatment course of 7-14 days for the acute infection, followed by an extended duration vancomycin course. Multiple publications on the utility of EDV regimens have been published but few include reported effectiveness outcomes associated with a prescribed treatment regimen. The purpose of this review is to evaluate the safety and efficacy data on extended duration vancomycin regimens used in recurrent clostridium treatment. Five articles, three case series and two randomized open-label clinical trials, were identified which included both elements. Outcomes were evaluable in 174 patients, 31 from randomized trials, with prior average recurrent episodes ranging from 3 to 4. Vancomycin dose ranged from 3500 to >6800 mg with therapy durations extending from 21 days to over 60 days. Follow-up duration ranged from 10 weeks to 12 months. Case series reported success rates for EDV in rCDI from 61% to 100%, while randomized trials found lower success rates from 26% to 58%. Taper and pulse regimens reported superior outcomes compared to pulse-only regimens, 58-100% versus 26-81%, respectively. Comparative EDV data is limited. Current available data supports an EDV regimen which includes both a daily dosing taper followed by an every 48 or 72 h pulse. Competing Interests: Conflict of interest statement: The authors declare no conflicts of interest in preparing this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|